Cart
sales@molnova.com
Sparteine sulfate
CAS No. 299-39-8
Sparteine sulfate( —— )
Catalog No. M18386 CAS No. 299-39-8
Sparteine sulfate is a class 1a antiarrhythmic agent and a sodium channel blocker. It can chelate the bivalents calcium and magnesium.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 95 | Get Quote |
|
| 10MG | 170 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSparteine sulfate
-
NoteResearch use only, not for human use.
-
Brief DescriptionSparteine sulfate is a class 1a antiarrhythmic agent and a sodium channel blocker. It can chelate the bivalents calcium and magnesium.
-
DescriptionSparteine sulfate is a class 1a antiarrhythmic agent and a sodium channel blocker. It can chelate the bivalents calcium and magnesium.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorSodium Channel
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number299-39-8
-
Formula Weight332.46
-
Molecular FormulaC15H28N2O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=S(=O)(O)O.C1CCCN2C[C@@H]3C[C@@H](CN4CCCC[C@@H]34)[C@@H]12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gawali VS, et al. C2-Modified Sparteine Derivatives Are a New Class of Potentially Long-Acting Sodium Channel Blockers. ChemMedChem. 2017 Nov 22;12(22):1819-1822.
molnova catalog
related products
-
PAN-90806
PAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM).
-
AG-13958
AG-13958 (AG-013958) a potent VEGFR tyrosine kinase inhibitor ?for the treatment of age-related macular degeneration.
-
8-O-Acetylshanzhisid...
8-O-Acetylshanzhiside methylester has potential against cerebral ischemic injury, and its protective effect on oxygen-glucose deprivation-induced injury might be due to the suppression of intracellular Ca2+ elevation and caspase-3 activity.
